Related Experiment Video
Updated: Jun 1, 2026

09:11
Synthesis of Near-Infrared Emitting Gold Nanoclusters for Biological Applications
Published on: March 22, 2020
Gold nanoparticle-fluorophore complex for conditionally fluorescing signal mediator
Jianting Wang1, Samuel Achilefu, Michael Nantz
1Department of Chemical Engineering University of, Louisville, KY 40292, United States.
Analytica Chimica Acta
|May 24, 2011
Summary
Gold nanoparticles (GNPs) can enhance or quench fluorescence for disease detection. A new near-infrared agent uses GNPs and a peptide spacer to detect cancer-specific enzymes like urokinase type plasminogen activator (uPA).
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Optical Physics
Background:
- Fluorescent contrast agents are crucial for disease detection.
- Gold nanoparticles (GNPs) offer unique plasmonic properties for manipulating fluorescence.
- Understanding GNP-fluorophore interactions is key to developing advanced imaging agents.
Purpose of the Study:
- To theoretically analyze fluorescence alteration mechanisms by GNPs.
- To investigate factors influencing fluorescence quenching and enhancement.
- To develop a novel GNP-based near-infrared contrast agent for enzyme detection.
Main Methods:
- Theoretical analysis of GNP-fluorophore interactions.
- Simulation of fluorescence quenching and enhancement based on GNP size, fluorophore properties, and distance.
- Design and conjugation of a near-infrared fluorophore (Cypate) to GNPs via a peptide spacer sensitive to urokinase type plasminogen activator (uPA).
Main Results:
- Fluorescence quenching is significant when excitation/emission wavelengths match the GNP resonance peak.
- Shorter GNP-fluorophore distances and larger GNPs enhance quenching.
- Near-infrared fluorophores with low quantum yields are more prone to enhancement; a uPA-sensitive agent was successfully developed showing quenched fluorescence until cleaved by uPA.
Conclusions:
- GNP-fluorophore interactions can be precisely controlled for sensing applications.
- The developed Cypate-conjugated GNP contrast agent shows high specificity for uPA.
- This technology holds promise for cancer diagnosis and detection of other enzyme-related diseases.

